CA2364484A1 - Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques - Google Patents

Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques Download PDF

Info

Publication number
CA2364484A1
CA2364484A1 CA002364484A CA2364484A CA2364484A1 CA 2364484 A1 CA2364484 A1 CA 2364484A1 CA 002364484 A CA002364484 A CA 002364484A CA 2364484 A CA2364484 A CA 2364484A CA 2364484 A1 CA2364484 A1 CA 2364484A1
Authority
CA
Canada
Prior art keywords
seq
group
tyr
ile
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364484A
Other languages
English (en)
Inventor
Kathleen Rodgers
Gere Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364484A1 publication Critical patent/CA2364484A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Abstract

La présente invention concerne des méthodes, des compositions pharmaceutiques, des milieux de culture cellulaire améliorés et des trousses permettant de stimuler la prolifération de myocytes et la réparation des tissus myocardiques suite à une blessure myocardique par contact avec un angiotensinogène, une angiotensine I (AI), des analogues d'AI, des fragments d'AI et leurs analogues, une angiotensine II (AII), des analogues d'AII, des fragments d'AII et leurs analogues et/ou des agonistes de récepteur de type 2 d'AII AT¿2?.
CA002364484A 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques Abandoned CA2364484A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12367899P 1999-03-09 1999-03-09
US60/123,678 1999-03-09
US15187499P 1999-08-31 1999-08-31
US60/151,874 1999-08-31
PCT/US2000/006198 WO2000053211A2 (fr) 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques

Publications (1)

Publication Number Publication Date
CA2364484A1 true CA2364484A1 (fr) 2000-09-14

Family

ID=26821778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364484A Abandoned CA2364484A1 (fr) 1999-03-09 2000-03-09 Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques

Country Status (4)

Country Link
EP (1) EP1158997A2 (fr)
AU (1) AU3734900A (fr)
CA (1) CA2364484A1 (fr)
WO (1) WO2000053211A2 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589938B2 (en) * 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1575517B1 (fr) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DE602004030535D1 (de) 2003-02-19 2011-01-27 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
WO2005062955A2 (fr) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Anticorps anti-trkc agonistes et procedes d'utilisation
ES2338344T3 (es) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
EP2405933A1 (fr) * 2009-03-13 2012-01-18 Medtronic, Inc Procédé de traitement d'insuffisance cardiaque
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
WO2013008185A1 (fr) 2011-07-14 2013-01-17 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CA2906624A1 (fr) 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicreine plasmatique
JP2016520058A (ja) 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション 抗グルカゴン受容体抗体およびその使用方法
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
CA2947148C (fr) 2014-04-30 2022-02-08 Pfizer Inc. Conjugues medicament-anticorps anti-ptk7
WO2016020799A1 (fr) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Méthodes pour réduire le cholestérol ldl
EP3193928A1 (fr) 2014-08-06 2017-07-26 Rinat Neuroscience Corp. Méthodes destinées à réduire le cholestérol ldl
WO2016034968A1 (fr) 2014-09-02 2016-03-10 Pfizer Inc. Anticorps thérapeutique
EP3197492A1 (fr) 2014-09-23 2017-08-02 Pfizer Inc Traitement avec des anticorps anti-pcsk9
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
MY196625A (en) 2015-04-13 2023-04-23 Pfizer Therapeutic Antibodies and Their Uses
CA2993026A1 (fr) 2015-07-21 2017-01-26 Dyax Corp. Inhibiteur d'anticorps monoclonal du facteur xiia
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
TWI727380B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
JP2019529463A (ja) 2016-09-23 2019-10-17 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 群発頭痛の治療方法
WO2018064515A1 (fr) 2016-09-30 2018-04-05 Academia Sinica Microarn let-7 et transformation de l'axe du récepteur du facteur de croissance transformant bêta iii en tant que cible pour des lésions cardiaques
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
WO2018160896A1 (fr) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Sélection de patients atteints de céphalées présentant une réponse à des anticorps dirigés contre un peptide lié au gène de la calcitonine
KR20190124753A (ko) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. 항-gitr 항체 및 이의 사용 방법
CA3059542A1 (fr) 2017-04-12 2018-10-18 Pfizer Inc. Anticorps ayant une affinite conditionnelle et leurs procedes d'utilisation
JP7034183B2 (ja) 2017-06-13 2022-03-11 ボストンジーン コーポレイション 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法
JP2020527558A (ja) 2017-07-13 2020-09-10 マサチューセッツ インスティテュート オブ テクノロジー シナプス機能を増強するためのｈｄａｃ２−ｓｐ３複合体の標的化
AU2018303333B2 (en) * 2017-07-17 2023-02-09 Monash University Angiotensin receptor agonists and uses thereof
WO2019018647A1 (fr) 2017-07-20 2019-01-24 Pfizer Inc. Anticorps anti-gd3 et conjugués anticorps-médicament
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
EP3692370A2 (fr) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles et procédés destinés à la thérapie personnalisée du cancer
US11613581B2 (en) 2017-10-27 2023-03-28 Pfizer, Inc. Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
CA3045370A1 (fr) 2018-06-08 2019-12-08 Pfizer Inc. Methodes de traitement de la maladie metabolique
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3152623A1 (fr) 2019-10-11 2021-04-15 Richard D. Cummings Anticorps anti-tn et leurs utilisations
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
WO2021224850A1 (fr) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Peptides masques et anticorps anti-ptk7 masqués les comprenant
EP4182346A1 (fr) 2020-07-17 2023-05-24 Pfizer Inc. Anticorps thérapeutiques et leurs utilisations
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022232615A1 (fr) 2021-04-29 2022-11-03 Bostongene Corporation Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
WO2023091968A1 (fr) 2021-11-17 2023-05-25 Disc Medicine, Inc. Méthodes de traitement de l'anémie causée par une maladie rénale
WO2023147177A1 (fr) 2022-01-31 2023-08-03 Bostongene Corporation Techniques d'apprentissage automatique pour cytométrie
WO2024015561A1 (fr) 2022-07-15 2024-01-18 Bostongene Corporation Techniques de détection d'une déficience de recombinaison homologue (hrd)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1333034B1 (fr) * 1993-09-24 2010-07-14 University Of Southern California Utilisation d'analogues d'angiotensine II pour la réparation tissulaire
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts

Also Published As

Publication number Publication date
WO2000053211A2 (fr) 2000-09-14
AU3734900A (en) 2000-09-28
EP1158997A2 (fr) 2001-12-05
WO2000053211A3 (fr) 2001-01-25

Similar Documents

Publication Publication Date Title
CA2364484A1 (fr) Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
US7118748B1 (en) Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US7786085B2 (en) Method for treating a patient undergoing chemotherapy
AU755943B2 (en) Methods to increase blood flow to ischemic tissue
AU706333B2 (en) Use of angiotensin III and analogs thereof in tissue repair
CA2319701C (fr) Procede pour promouvoir l'erythropoiese
JP4347522B2 (ja) 創傷治癒組成物
US6762167B1 (en) Methods for treating a patient undergoing chemotherapy
US6747008B1 (en) Methods for treating and preventing alopecia
AU759285B2 (en) Methods to increase white blood cell survival after chemotherapy
US7122523B2 (en) Methods for inhibiting tumor cell proliferation
US6730775B1 (en) Methods for limiting scar and adhesion formation
CA2367107C (fr) Procede pour limiter la formation de cicatrices et d'adherences
US20020049162A1 (en) Methods for inhibiting smooth muscle cell proliferation
WO2001044270A2 (fr) Procedes permettant de traiter et d'empecher des complications diabetiques
WO2001098325A1 (fr) Procedes de traitement et de prevention de l'alopecie
CA2442340A1 (fr) Proceder pour limiter la formation de cicatrices et d'adherences
CA2339328A1 (fr) Proteines associees au recepteur de benzodiazepine du type peripherique, clonage, expression et procedes d'utilisation de celles-ci
MXPA01001638A (en) Methods to increase blood flow to ischemic tissue
MXPA00011112A (en) Methods to increase white blood cell survival after chemotherapy
MXPA00007509A (en) Method of promoting erythropoiesis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead